Isavuconazole: Mechanism of Action, Clinical Efficacy, and Resistance

Overview

Journal J Fungi (Basel)

Date 2020 Dec 2

PMID 33260353

Citations 43

Authors

Misti Ellsworth

Luis Ostrosky-Zeichner

Affiliations

Soon will be listed here.

Abstract

Increasing incidence of invasive fungal infections combined with a growing population of immunocompromised hosts has created a rising need for antifungal agents. Isavuconazole, a second-generation broad-spectrum triazole with activity against yeasts, dimorphic fungi, and molds, has a favorable safety profile and predictable pharmacokinetics. Patients typically tolerate isavuconazole well with fewer drug-drug interactions. Clinical trials have found it to be noninferior to voriconazole for invasive aspergillosis, an alternative therapy for salvage treatment of mucormycosis, and suitable for stepdown therapy with invasive candidiasis. Cross-resistance with other triazoles is common. More studies are needed to determine the role of isavuconazole in anti-mold prophylaxis in high-risk patients.

Citing Articles

The evolution of antifungal therapy: Traditional agents, current challenges and future perspectives.

Souza C, Bezerra B, Mellon D, de Oliveira H Curr Res Microb Sci. 2025; 8:100341.

PMID: 39897698 PMC: 11786858. DOI: 10.1016/j.crmicr.2025.100341.

Real-World Effectiveness and Safety of Isavuconazole Versus Amphotericin B for Patients with Invasive Mucormycosis.

Qin J, Bi H, Tang G, Liu X, Qu J, Lv X Microorganisms. 2025; 13(1).

PMID: 39858823 PMC: 11767576. DOI: 10.3390/microorganisms13010055.

The Significance of Mono- and Dual-Effective Agents in the Development of New Antifungal Strategies.

Zobi C, Algul O Chem Biol Drug Des. 2025; 105(1):e70045.

PMID: 39841631 PMC: 11753615. DOI: 10.1111/cbdd.70045.

Isolate Specific Transcriptome Changes Exerted by Isavuconazole Treatment in Candida auris.

Balla N, Kovacs F, Toth Z, Harmath A, Bozo A, Majoros L Mycopathologia. 2024; 190(1):5.

PMID: 39729249 DOI: 10.1007/s11046-024-00919-1.

Review and Current Perspectives on DNA Topoisomerase I and II Enzymes of Fungi as Study Models for the Development of New Antifungal Drugs.

Andrade-Pavon D, Gomez-Garcia O, Villa-Tanaca L J Fungi (Basel). 2024; 10(9).

PMID: 39330389 PMC: 11432948. DOI: 10.3390/jof10090629.

References

Perfect J, Cornely O, Heep M, Ostrosky-Zeichner L, Mullane K, Maher R . Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial. Mycoses. 2018; 61(7):420-429. PMC: 6490690. DOI: 10.1111/myc.12769. View

Kieu V, Jhangiani K, Dadwal S, Nakamura R, Pon D . Effect of isavuconazole on tacrolimus and sirolimus serum concentrations in allogeneic hematopoietic stem cell transplant patients: A drug-drug interaction study. Transpl Infect Dis. 2018; 21(1):e13007. DOI: 10.1111/tid.13007. View

Ullmann A, Aguado J, Arikan-Akdagli S, Denning D, Groll A, Lagrou K . Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018; 24 Suppl 1:e1-e38. DOI: 10.1016/j.cmi.2018.01.002. View

Zurl C, Waller M, Schwameis F, Muhr T, Bauer N, Zollner-Schwetz I . Isavuconazole Treatment in a Mixed Patient Cohort with Invasive Fungal Infections: Outcome, Tolerability and Clinical Implications of Isavuconazole Plasma Concentrations. J Fungi (Basel). 2020; 6(2). PMC: 7344482. DOI: 10.3390/jof6020090. View

Jorgensen K, Astvad K, Hare R, Arendrup M . EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates. Antimicrob Agents Chemother. 2019; 63(6). PMC: 6535523. DOI: 10.1128/AAC.00073-19. View

Townsend R, Akhtar S, Alcorn H, Berg J, Kowalski D, Mujais S . Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics. Eur J Clin Pharmacol. 2017; 73(6):669-678. PMC: 5423998. DOI: 10.1007/s00228-017-2213-7. View

Bongomin F, Gago S, Oladele R, Denning D . Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision. J Fungi (Basel). 2018; 3(4). PMC: 5753159. DOI: 10.3390/jof3040057. View

Schmitt-Hoffmann A, Roos B, Heep M, Schleimer M, Weidekamm E, Brown T . Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in.... Antimicrob Agents Chemother. 2005; 50(1):279-85. PMC: 1346775. DOI: 10.1128/AAC.50.1.279-285.2006. View

Ricotta E, Lai Y, Babiker A, Strich J, Kadri S, Lionakis M . Invasive Candidiasis Species Distribution and Trends, United States, 2009-2017. J Infect Dis. 2020; 223(7):1295-1302. PMC: 8030726. DOI: 10.1093/infdis/jiaa502. View

10.

Arendrup M, Jensen R, Meletiadis J . In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order. Antimicrob Agents Chemother. 2015; 59(12):7735-42. PMC: 4649229. DOI: 10.1128/AAC.01919-15. View

11.

Ilharco M, Pereira C, Moreira L, Proenca A, do Carmo Fevereiro M, Lampreia F . Rhinoorbital mucormycosis in the immunocompetent: Experience with Isavuconazole. IDCases. 2019; 18:e00591. PMC: 6700484. DOI: 10.1016/j.idcr.2019.e00591. View

12.

Espinel-Ingroff A, Chowdhary A, Gonzalez G, Guinea J, Hagen F, Meis J . Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method. Antimicrob Agents Chemother. 2014; 59(1):666-8. PMC: 4291414. DOI: 10.1128/AAC.04055-14. View

13.

Patterson T, Thompson 3rd G, Denning D, Fishman J, Hadley S, Herbrecht R . Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016; 63(4):433-42. PMC: 4967611. DOI: 10.1093/cid/ciw444. View

14.

Andes D, Kovanda L, Desai A, Kitt T, Zhao M, Walsh T . Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials. Antimicrob Agents Chemother. 2018; 62(7). PMC: 6021624. DOI: 10.1128/AAC.00585-18. View

15.

Schmitt-Hoffmann A, Roos B, Maares J, Heep M, Spickerman J, Weidekamm E . Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother. 2005; 50(1):286-93. PMC: 1346776. DOI: 10.1128/AAC.50.1.286-293.2006. View

16.

Pfaller M, Diekema D . Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007; 20(1):133-63. PMC: 1797637. DOI: 10.1128/CMR.00029-06. View

17.

Brown G, Denning D, Gow N, Levitz S, Netea M, White T . Hidden killers: human fungal infections. Sci Transl Med. 2012; 4(165):165rv13. DOI: 10.1126/scitranslmed.3004404. View

18.

Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll A, Skiada A . ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2016; 102(3):433-444. PMC: 5394968. DOI: 10.3324/haematol.2016.152900. View

19.

Bongomin F, Maguire N, Moore C, Felton T, Rautemaa-Richardson R . Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events. Mycoses. 2018; 62(3):217-222. DOI: 10.1111/myc.12885. View

20.

Gallagher J, Dodds Ashley E, Drew R, Perfect J . Antifungal pharmacotherapy for invasive mould infections. Expert Opin Pharmacother. 2003; 4(2):147-64. DOI: 10.1517/14656566.4.2.147. View